Ustekinumab (Anti-IL-12/23p40 Monoclonal Antibody) in Patients With Leukocyte Adhesion Deficiency Type 1 (LAD1) Who Have Inflammatory Pathology
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03366142|
Recruitment Status : Suspended (Enrollment paused until PI investigates if patient lesions may be due to study drug.)
First Posted : December 8, 2017
Last Update Posted : October 19, 2018
National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Institute of Allergy and Infectious Diseases (NIAID) )
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Suspended|
|Estimated Primary Completion Date :||January 31, 2021|
|Estimated Study Completion Date :||May 31, 2021|
Hajishengallis G, Moutsopoulos NM. Role of bacteria in leukocyte adhesion deficiency-associated periodontitis. Microb Pathog. 2016 May;94:21-6. doi: 10.1016/j.micpath.2015.09.003. Epub 2015 Sep 14. Review.
Hajishengallis G, Moutsopoulos NM, Hajishengallis E, Chavakis T. Immune and regulatory functions of neutrophils in inflammatory bone loss. Semin Immunol. 2016 Apr;28(2):146-58. doi: 10.1016/j.smim.2016.02.002. Epub 2016 Feb 28. Review.